Loring Wolcott & Coolidge Fiduciary Advisors’s Filana Therapeutics FLNA Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-95	Closed	-$2.33K	–	649
2023 Q2	$2.33K	Hold	95	–	–	﹤0.01%	608
2023 Q1	$2.29K	Hold	95	–	–	﹤0.01%	569
2022 Q4	$2.81K	Hold	95	–	–	﹤0.01%	547
2022 Q3	$4K	Hold	95	–	–	﹤0.01%	560
2022 Q2	$3K	Hold	95	–	–	﹤0.01%	597
2022 Q1	$4K	Hold	95	–	–	﹤0.01%	601
2021 Q4	$4K	Hold	95	–	–	﹤0.01%	669
2021 Q3	$6K	Hold	95	–	–	﹤0.01%	647
2021 Q2	$8K	Buy	+95	New	+$5.09K	﹤0.01%	681

Other funds holding FLNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's FLNA Position: Q3 2023 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Filana Therapeutics (FLNA) in Q3 2023, closing a stake of 95 shares — an estimated $2.33K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in FLNA in Q2 2021 and held it in 9 quarters. The position peaked at $8K in Q2 2021. 140 funds tracked by Wall St. Rank hold FLNA as of Q3 2023.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Filana Therapeutics position as of Q3 2023 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 95 Filana Therapeutics shares in Q3 2023, an estimated $2.33K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Filana Therapeutics in Q2 2021 and held it in 9 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Filana Therapeutics position peaked at $8K in Q2 2021.
140 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2023.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.